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Background: Human papillomavirus (HPV) types 16 and 18 are the high-risk, sexually
transmitted infectious causes of most cervical intraepithelial neoplasias (CIN) or
cancers. While efficacious vaccines to reduce the sexual acquisition of these high-risk
HPVs have recently been introduced, no virus-targeted therapies exist for those
already exposed and infected. Considering the oncogenic role of the transforming
(E6 and E7) genes of high-risk HPVs in the slow pathogenesis of cervical cancer, we
hypothesize that timely disruption or abolition of HPV genome expression within
pre-cancerous lesions identified at screening may reverse neoplasia. We aimed to
derive model zinc finger nucleases (ZFNs) for mutagenesis of the genomes of two
high-risk HPV (types 16 & 18).
Methods and results: Using ZiFiT software and the complete genomes of HPV
types16 and 18, we computationally generated the consensus amino acid sequences
of the DNA-binding domains (F1, F2, & F3) of (i) 296 & 327 contextually unpaired
(or single) three zinc-finger arrays (sZFAs) and (ii) 9 & 13 contextually paired (left and
right) three- zinc-finger arrays (pZFAs) that bind genomic DNA of HPV-types 16 and
18 respectively, inclusive of the E7 gene (s/pZFAHpV/E7). In the absence of
contextually paired three-zinc-finger arrays (pZFAs) that bind DNA corresponding to
the genomic context of the E6 gene of either HPV type, we derived the DNA
binding domains of another set of 9 & 14 contextually unpaired E6 gene-binding
ZFAs (sZFAE6) to aid the future quest for paired ZFAs to target E6 gene sequences in
both HPV types studied (pZFAE6). This paper presents models for (i) synthesis of
hybrid ZFNs that cleave within the genomic DNA of either HPV type, by linking the
gene sequences of the DNA-cleavage domain of the FokI endonuclease FN to the
gene sequences of a member of the paired-HPV-binding ZFAs (pZFAHpV/E7 + FN), and
(ii) delivery of the same into precancerous lesions using HPV-derived viral plasmids
or vectors.
Conclusions: With further optimization, these model ZFNs offer the opportunity to
induce target-mutagenesis and gene-therapeutic reversal of cervical neoplasia
associated with HPV types 16 & 18.© 2012 Wayengera; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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High-risk human papillomaviruses (HPVs) as oncogenic agents associated with cervical
neoplasia
Human papillomaviruses (HPVs) are circular double stranded (ds) deoxyribonucleic acids
(DNA) viruses of the genus alphapapillomavirus and family papillomavirus. Productive
infection with HPVs only occurs within the stratified epithelium of the skin or mucous
membranes [1]. Although there are over 200 HPV types, and 30 to 40 of these are sexually
transmitted, only types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 are denoted ‘high-
risk’ HPVs [2,3]. Infection with these HPV types may lead to the development of cervical,
penile or anal intraepithelial neoplasia. This is because most HPV infections are tempor-
ary, being eventually cleared by the immune system (70% and 90% in the first and second
year following infection, respectively) with little or no long-term clinical significance [4].
In some individuals (representing 5% to 10% of infected women), however, the infection
persists and could increase the risk for development of pre-cancerous lesions of the cer-
vix, which can progress to invasive cervical cancer [4]. Cervical cancer is the cause of sub-
stantial morbidity and mortality among women world-wide. Each year, an estimated
490,000 cases of cervical cancer occur, resulting in approximately 270,000 deaths [1,2].
High-risk HPVs induce malignant transformation (neoplasia) and promote tumor growth
through their early oncogenes E6 (HpVgp1) and E7 (HpVgp2). On the one hand, E6,
which has a close relationship with the cellular protein E6-AP (E6-associated protein),
mediates ubiquitin binding to the p53 protein, thereby flagging it for proteosomal degra-
dation [5]. Degradation of p53, a protein that primarily prevents cell growth and stimu-
lates apoptosis in the presence of DNA damage, promotes neoplasia. When present in
normal levels, p53 also upregulates the p21 protein, which blocks the formation of
the cyclin D/Cdk4 complex. This prevents the phosphorylation of retinoblastoma pro-
tein (pRB) and in turn halts cell cycle progression by preventing the activation of the
eukaryotic transcription factor E2F. In short, p53 is either absent or its levels are
greatly reduced within cervical cancer cells [6,7]. On the other hand, the E7 oncopro-
tein induces neoplasia by binding to and acting on multiple functional partners, not-
ably retinoblastoma protein (pRB) and the class I histone deacetylases HDAC1 and
HDAC2 [8-10]. Specifically, E7 destabilizes pRB levels through cullin 2–mediated pro-
teasomal degradation [8]. E7 also indirectly binds to HDAC1 and HDAC2 as well as
the reverse transcriptase (hTERT) region of telomerase via sequences in its zinc-
finger domain [9]. While mutations within the zinc-finger domain of E7 do not affect
its propensity to bind to and degrade pRB, they do abrogate its ability to immortalize
cells, suggesting that both activities of E7 are required for immortalization [7-10].
Overall, cervical cancer cells can be said to be addicted to and or to thrive on the ex-
pression of the E6 and E7 proteins of high-risk HPVs.Limitation of existing treatment and prevention modalities for ‘high-risk’ HPV
The slow neoplastic process following infection with high-risk HPVs, which usually
takes 15–20 years, provides many opportunities for early detection and treatment of
the pre-cancerous lesion. Specifically, progression to invasive cancer can almost always
be prevented when standard prevention strategies are applied. In most countries,
cervical screening using a Papanicolaou (Pap) test [11] or liquid-based cytology [12] is
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screening for HPVs or diagnostic testing (detecting E6, E7, or p16 mRNA) is now avail-
able [13-15]. If and when abnormal cells are found, women are invited to have a col-
poscopy with visual inspection under acetoacetic acid (VIUA). During a colposcopic
inspection, biopsies can be taken and abnormal areas removed with simple procedures,
typically by wedge- biopsy, cauterizing loop, freezing (cryotherapy), or chemo-/radio-
therapy [16]. Treating abnormal cells in this way can halt the initiated development of
cervical cancer [17]. However, only a few high-risk women, particularly within the
developing world, ever get the timely test to detect abnormal cervical lesions. In
addition, only a minority of those who are tested and are positive ever receive the ther-
apy required to arrest disease. This may be attributed to inadequate follow-up and poor
referral systems within poorly-resourced country health centers. Recent development of
HPV vaccines (Cervarix and Gardasil), which when effectively used can prevent pri-
mary infection with the HPV types (16 and 18) that cause 70% of cervical cancers, has
generated optimism that the global incidence of cervical cancer may be subdued
[18,19]. It is nevertheless important to acknowledge that (i) coverage of HPV vaccin-
ation remains low within resource-limited yet cervical cancer-high incidence settings,
and (ii) the current HPV vaccines are only effective when offered to girls who are not
yet sexually active and have therefore never been exposed to high-risk HPVs.
Overall, the picture described above underscores the relevance of investing in devel-
opment of specifically HPV-targeted treatments as a complementary public health
strategy for controlling the global incidence of cervical cancer. More recently, Lin et al.
[20] have proposed and experimentally tested the use of proteosome and histone de-
acetylase (HDAC) inhibitors as novel HPV-targeted treatments for cervical cancer.The alternate option of directly disrupting or abolishing HPV gene expression
Bacteria endowed with the restriction modification (R-M) system exhibit amazing re-
sistance to tropism by the xenogeneic DNA of bacteria-infecting viruses, bacterio-
phages. RM systems can be said to be a primitive form of the many restriction factors
that have recently been found to possess innate antiviral properties [21-23]. I [21] pre-
viously proposed using the anti-phage DNA machinery inherent within bacterial RM
systems as a model for devising eukaryotic virus gene therapies. Towards this goal, I
and colleagues [22,23] identified several bacterially-derived restriction enzymes with
potential to cleave the DNA of human-infecting viruses, including frequency and site
mapping of HIV-1, HIV-2 and several other SIV gene cleavages using a proviral DNA
model [23]. However, most naturally-occurring bacterial restriction enzymes (aka
REases) previously found to possess high potency (to slice or disrupt) against human
infecting viruses in this manner were observed to cleave at palindromic sites that are
short and equally prevalent within the human host genome, thereby raising concerns
about in-situ safety. Our failure to address this priority milestone limited the use of
those REase-therapeutic precursors to modeling and the extracellular space [22]. The
long-term goal in the field of RM enzymatic therapeutics has been to generate synthetic
restriction endonucleases with longer recognition sites specific only for the eukaryotic
virus by mutating or engineering existing enzymes. Zinc finger nucleases (ZFNs) are
artificial, hybrid restriction enzymes created by covalently linking a DNA-binding zinc
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age domain (or simply FN) of the Flavobacterium okeanokoites restriction endonuclease
FokI [24]. ZFNs have recently emerged as a potentially powerful tool for fighting
eukaryotic viruses, either by primarily editing host genomes, or secondarily targeting
incoming viral genomes [24-32]. On the one hand, Perez et al. [29], using engineered
ZFNs targeting human CCR5, previously demonstrated the establishment of HIV-1
resistance in CD4+ T cells through generation of a double-strand break (DSB) at prede-
termined sites in the CCR5 coding region upstream of the natural CCR5D32 mutation.
More recently, Holt et al. [30] demonstrated control of HIV-1 infection within NSG-
mice transplanted with human hematopoietic stem/progenitor cells modified by zinc-
finger nucleases targeting CCR5. On the other hand, with the intent of disrupting
incoming viral genomes, we recently identified DNA binding domains of ZFNs to use
as gene-therapeutics against proviral HIV DNA and HSV-II [31,32].
In the light of the above literature, we hypothesized that target mutagenesis of those
high-risk forms of HPVs using ZFNs may possess potential for genetic therapy and re-
versal of cervical cancer in-situ.
The aim of this study was to identify and model DNA-binding domains of zinc finger
arrays (ZFAs) as precursors for (i) synthesizing ZFNs for target mutagenesis of two high-
risk HPV (types 16 & 18) –genomes, and development of a novel gene-therapeutic arma-
ment for reversing the primary oncogenic processes leading to cervical neoplasia.Methods and results
(a) Database of DNA-binding domains of contextually unpaired three zinc-finger arrays
targeting HPV types 16 and 18 genomic DNA
First, using Context-Dependent Assembly (CoDA) inherent in the ZiFiT-ZFA software of
the zinc finger consortium [33-36] and the complete genomes of HPV types 16 and 18,
we computationally generated the consensus amino acid sequences of the DNA binding
domains or F1, F2 & F3 helices of 296 (see, Additional file 1 and Figure 1) and 327 (see,
Additional file 2 and Figure 2) unpaired (single, either left or right) three zinc- finger (Zif)
arrays (sZFAs) for targeting genomic DNA of HPV types 16 and 18, respectively. These
ZFAs are henceforth denoted sZFAHpV16 and sZFAHpV18 respectively, or simply sZFAHpV.
In principle, the FASTA formats of each virus type’s complete genomic DNA sequences
(NCBI Accession #: |NC_001526.2| and |NC_001357.1| or IDs: 5607 and 5608, respect-
ively) were individually fed into the user-interface preset to assemble three finger arrays.
Although the HPV genomes do not contain intronic sequences, the exon/intron case-Figure 1 Schematics of zinc finger arrays targeting HPV type 16 genomic DNA. This figure offers a
diagrammatic illustration of loci of action of zinc finger arrays that specifically bind to 9 bp nucleotide
sequences within the genomic DNA context of HPV type 16. Hits (blue, green, and gold bars) represent
targets along the gene (red bars). ZFAs hits in the graphic are color-coded on the basis of spacer size
(5 bp = Blue; 6 bp =Green; 7 bp =Gold).
Figure 2 Schematics of zinc finger arrays binding to HPV type 18 genomic DNA. This figure offers a
diagrammatic illustration of loci of action of zinc finger arrays that specifically bind to 9 bp nucleotide
sequences within the genomic DNA context of HPV type 18. Hits (blue, green, and gold bars) represent
targets along the gene (red bars). ZFA hits in the graphic are color-coded on the basis of spacer size
(5 bp = Blue; 6 bp =Green; 7 bp =Gold).
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rithm is necessary to distinguish between intron and exon sequences by denoting exons
in uppercase and introns in lowercase. Overall, for either virus type, we derived DNA-
binding domains of unpaired or single three-ZFAs (sZFAs) capable of specifically recog-
nizing and binding to consecutive 9 bp sequences across the entire genome (see Figures 1
and 2, respectively). Analyses of the issuing cleavage patterns revealed that the highest in-
cidence of unpaired ZFA-binding HPV type 16 genomic DNA is situated within the first
and last 1,581 bp (20% of 7,905 bp) of the complete HPV type 16 genome (genomic con-
text: before 0.2 and after 0.8, respectively) (see Figure 1). According to Zheng and Baker
[37], the HPV genome can be organized into three major regions: early, late, and a long
control region (LCR or non-coding region [NCR]), which are separated by two polyadeny-
lation (pA) sites: early pA (AE) and late pA (AL). The early region of a papillomavirus gen-
ome occupies over 50% of the genome from its 5′ end and encodes six common open
reading frames (E1, E2, E4, E5, E6 and E7) that translate their respective proteins. Two
additional ORFs, E3 and E8, were assigned to this region initially. However, only the E8
ORF in bovine papilloma virus-1 and HPV-31 have so far been proven to encode a spliced
E8^E2C fusion protein, which functions as a negative regulator of viral transcription and
replication. The late region of every papillomavirus genome, covering almost 40% of the
genome, lies downstream of the early region and encodes L1 and L2 ORFs for translation
of a major (L1) and a minor (L2) capsid protein. The long control region (LCR), a seg-
ment of about 850 bp (10% of the HPV genome), has no protein-coding function, but
bears the origin of replication as well as multiple transcription factor binding sites that are
important in regulation of RNA polymerase II-initiated transcription from viral early as
well as late promoters. On the basis of this genome structure, those ZFAs binding to the
5′ end 20% would fall under the early region, while the 3′ end 20% falls both under the
late and LCR region. For HPV type 18, on the other hand, despite an occurrence of ZFAs
with DNA-binding domains able to target 9 bp sequences distributed randomly across al-
most all its genome, the highest incidence of ZFAs with HPV-type 18 genomic DNA
binding-domains was found to be situated within the last 1,571 bp (20% of the total gen-
omic 7,857 bp) of the complete genome (genomic context: 0.8-1.00) (see Figure 2). In the
context of the HPV genome structure provided by Zheng and Baker [37], this 3′ end falls
under the late and long control region (LCR) of all papillomavirus genomes, and encodes
L1 and L2 ORFs for translation of a major (L1) and a minor (L2) capsid protein, alongside
the LCR regional origin of replication plus multiple transcription factors [37]. Each of
these contextually unpaired or single zinc finger arrays (sZFAs) is composed of three zinc
fingers (Zif or simply ZF). Zifs or ZFs are protein motifs that each possesses two beta
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conserved cysteine and histidine (C2H2) residues [38-40]. Residues 1 to 6 (numbered rela-
tive to the start) of the alpha-helix mediate target binding and recognition of triplets of
DNA sequences through the formation of base-specific contacts in the major groove of the
double-stranded target DNA (for illustration, see Additional file 1 and Additional file 2)
[38-41]. Several Zifs/ZFs can be linked together, as is the case in the sZFAHpV16 and
sZFAHpV18 databases, in order to yield a contextually unpaired multi-finger array capable
of recognizing a longer and thereby preferentially unique sequence in any target double-
stranded genomic DNA, aside from the host. As already shown in Additional file 1 and
Additional file 2, several such contextually unpaired ZFAs were uncovered with target-
binding potency across the entire genomic contexts of either HPV type 16 or 18 DNA.(b) Database of DNA-binding domains of contextually paired three zinc-finger arrays tar-
geting HPV types 16 and 18 genomic DNA specific zinc finger nucleases
Second, using Context-Dependent Assembly (CoDA) inherent in the ZiFiT-ZFN soft-
ware of the zinc finger consortium [33-36] and the complete genomes of HPV types 16
and 18, we computationally compiled the amino acid sequences of the alpha-helical
DNA-binding domains of 9 and 13 paired three zinc-finger arrays targeting HPV types
16 and 18 genomic DNA, respectively (see Additional file 3 and Additional file 4, re-
spectively). Throughout our assembly of the DNA-binding domains of these paired
ZFA (pZFAs), all ZiFiT-ZFN algorithms were pre-set as they were for derivation of the
unpaired ZFAs (sZFAs) above, except that a 5, 6, or 7 base-pair (bp) overlapping se-
quence was selected in addition. Because ZFNs function as dimers, it is these paired
ZFAs (pZFAs) assembled in this section of the results that are intended for engineering
ZFNs that cleave the genomes of the study HPV types, as modeled further below [38].
These paired ZFA (pZFAs) are henceforth denoted pZFAHpV16 and pZFAHpV18 respect-
ively, or simply pZFAHpV. Overall, pZFAHpV with demonstrable in-silico ability to bind
to target sequences at positions 0.45 (~3,557 bp), 0.75 (~5,929 bp), and across 0.85 to
0.90 within the HPV type 16 genomic DNA context were derived. These genomic con-
textual regions approximately correspond to sequences between the early region’s
hypothetical protein HpV16gp5 (context 3332-3619 bp) and the late region’s major L1
capsid protein (5,560-7,155 bp) (see Figure 3). In contrast, pZFAHpV capable of binding
at positions 0.1 (~786 bp), 0.25 (~1,964 bp), 0.45 (~3, 535 bp), 0.65 (~5,107 bp), 0.75
(~5,892 bp) and 0.85 (~6,679 bp) respectively within the HPV type 18 genomic DNA
context were derived. These regions correspond to the genomic contexts of the genes
E7, E1, E2, E3, E4, L2 and L1, respectively (see Figure 4). It is important to note that,
while we have generated pZFAHpV that are precursors for synthesizing HPV-specificFigure 3 Schematics of zinc finger nucleases cleaving HPV type 16 genomic DNA. This figure offers a
diagrammatic illustration of loci of action of zinc finger nucleases that target and cleave >18 bp (9x2 + 5, 6,
or 7) sequences within the genomic DNA context of HPV type 16. Hits (blue, green, and gold bars)
represent targets along the gene (red bars). ZFN hits in the graphic are color-coded on the basis of spacer
size (5 bp = Blue; 6 bp =Green; 7 bp =Gold).
Figure 4 Schematics of zinc finger nucleases cleaving HPV type 18 genomic DNA. This figure offers a
diagrammatic illustration of loci of action of zinc finger nucleases that target and cleave >18 bp (9x2 + 5, 6,
or 7) sequences within the genomic DNA context of HPV type 18. Hits (blue, green, and gold bars)
represent targets along the gene (red bars). ZFN hits in the graphic are color-coded on the basis of spacer
size (5 bp = Blue; 6 bp =Green; 7 bp =Gold).
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eled below (see section d of results).(c) Repository of DNA-binding domains of unpaired zinc finger arrays targeting HPV
types 16 and 18 E6 genes
Lastly, in the absence of any paired ZFA (pZFAs) that are precursors for engineering
ZFNs targeting within the genomic context corresponding to the E6 transforming gene
of either HPV type 16 (>gi|310698439:83-559|) or 18 (>gi|9626069:105–581), we fo-
cused our efforts on assembling another two databases of 9 (Figure 5) and 14 (Figure 6)
DNA-binding domains of unpaired or single ZFAs (sZFAs) that target this early gene
variant from HPV types 16 and 18, respectively. These sZFA databases offer us a basis
for creating novel E6-targeting pZFAs precursors of ZFNs, by (i) sequential pairing of
those neighboring sZFAs lying within the context of a desired pZFA target, and (ii)
in-vitro optimization [42]. Alternatively, those E6 gene binding sZFAs may be used
to enhance delivery of existing HPV-targeted treatments for cervical cancer such as
the proteosome and histone deacetylase (HDAC) inhibitors previously described by
Lin et al. [20].(d) Models for synthesis and delivery of ZFNs targeting HPV types 16 and 18
The following text describes the generation of models for (i) synthesis of hybrid ZFNs
to cleave within either HPV type’s genomic DNA by linking the gene sequences of the
DNA-cleavage domain of the FokI endonuclease-FN to gene sequences coding for
members of the paired-HPV-binding ZFAs (pZFAHpV/E7 + FN) and (ii) delivery of the
same into precancerous lesions using HPV-derived viral plasmids or vectors:
First, using an approach similar to that described by Kim et al. (1996), employing the
gene sequences of the DNA-cleavage domain of the Fok I endonuclease-FN (derived
from Flavobacterium okeanokoites and belonging to the type IIS class) and members of
a pair of ZFAs (pZFAs) (see Additional file 3 and Additional file 4, respectively) in our
databases provided in section b above, it is possible to fuse the two sequences to yieldFigure 5 Schematics of zinc finger arrays binding to HPV type 16 E6 gene. This figure offers a
diagrammatic illustration of loci of action of zinc finger arrays that specifically bind to 9 bp nucleotide
sequences within the DNA context of the HPV type 16 transforming gene, E6. Hits (blue, green, and gold
bars) represent targets along the gene (red bars). ZFA hits in the graphic are color-coded on the basis of
spacer size (5 bp = Blue; 6 bp=Green; 7 bp =Gold).
Figure 6 Schematics of zinc finger arrays binding to HPV type 18 E6 gene. This figure offers a
diagrammatic illustration of loci of action of zinc finger arrays that specifically bind to 9 bp nucleotide
sequences within the DNA context of the HPV type 18 transforming gene, E6. Hits (blue, green, and gold
bars) represent targets along the gene (red bars). ZFA hits in the graphic are color-coded on the basis of
spacer size (5 bp = Blue; 6 bp=Green; 7 bp =Gold).
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DNAs of HPV types 16 and 18, respectively (for the predicted corresponding ZFN-
cleavage sites, see Figures 3 and 4) [38]. The two individual components of the model
ZFNs (pZFAHpV and FN) are molecularly cloned into ZFN expression vectors in-vitro
using unique XbaI/NotI restriction sites [33-36,38-41]. Specifically, PCR amplification
of gene-sequences of each individual component is done using primers that introduce
XbaI/NotI sites as a strategy to enable a pair of the pZFAHpV + FN complex to be
inserted into alternative sites of Zinc Finger Consortia plasmids capable of recognizing
target sites with a 7 bp spacer [33,34]. In principle, since the desired effect of the ZFN
is achieved in-vivo by two paired zinc finger arrays (pZFAs) each fused to a nuclease
domain, two members of a pair (pZFAs) are sub-cloned. Dimerization of the FokI nu-
clease occurs in-vivo when both members of the pZFA bind their target sequence,
thereby ensuring that the two FokI nucleases attach to the target DNA in a particular
configuration in order to introduce a double strand break (DSB). Following actual syn-
thesis, it may be necessary to incorporate further improvements, say by (i) modular
analysis to add one, two or even three other ZFA on to our currently three-paired ZFAs
(pZFAs) so as to enhance specificity and avoid off-target genome toxicity [33-36]. In-
vitro assembly and testing for efficacy of the desired target-cleavage need to be done
pre-clinically say by (ii) using either a bacteria-one hybrid (B1H) or yeast one-hybrid
(Y1B) system, so as to inform and select the best ZFNs to use in-vivo [42]. Elsewhere,
(iii) the Fok1 cleavage domain has been modified as a strategy for generating a hybrid
capable of functionally interrogating the ZFN dimer interface so as to prevent homodi-
merization while still enhancing the efficiency of cleavage [42].
Second, an exact approach toward gene delivery and transduction of the ‘pre-
cancerous lesion’ cells with these ZFHpV + FN complexes in-vivo is theoretically pro-
posed. Specifically, we propose the use of human papillomavirus plasmids capable of
episomal replication in human cell lines, to deliver the diploid or paired copy of the
high-risk HPV-specific ZFN genotype, pZFHpV + FN. The pZFHpV + FN genotype may be
sub-cloned using similar PCR-primers to the ones proposed above for consortia plas-
mids, with tailored modifications to HPV plasmids or PsV. Sverdrup et al. [43] have
previously generated such human papillomavirus (HPV) plasmids containing the viral
E1 and E2 genes (or the E1 gene alone) and an origin of replication, which they simul-
taneously demonstrated to replicate to significant levels in the transfected human cer-
vical carcinoma C-33A cell line. Alternatively, HPV PsV encapsidation of the zinc
finger consortium’s plasmids carrying the pZFHpV + FN (see results of modeling above)
may suffice. Graham et al. [44], using such HPV PsV-encapsidation of DNA plasmids,
produced mucosal vaccine vectors expressing an experimental antigen derived from the
M and M2 proteins of respiratory syncytial virus. The same were shown to evoke
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Moreover, on the basis of light emission and immunofluorescence microscopy, it was
shown by immunization with HPV PsV-encapsidated luciferase- and red fluorescent
protein (RFP)-expressing plasmids that the HPV PsV-encapsidated plasmids induce
antigen expression restricted to the vaginal epithelium (an ideal target), although this
expression is only transient and further modifications of these HPV plasmids are
needed to ensure stable expression of the exogenous pZFHpV + FN genotype [45].(e) Software and databases
The National Center for Biotechnology Information (NCBI) HPV type 16 and 18 gen-




The two Zinc Finger Consortium’s CoDA-ZiFiT software used are available at the fol-
lowing URL: http://zifit.partners.org/ZiFiT/ChoiceMenu.aspx.Discussion
I present here databases of paired ZFAs (pZFA) that are precursors for engineering
ZFNs to target and cleave the genomic DNA of the two high-risk HPV types most asso-
ciated with cervical cancer. With the appropriate in-vivo gene-delivery and transduc-
tion plasmids or vectors, models of ZFNs synthesized from these pZFA may offer us
the means for targeted HPV mutagenesis and therapeutic reversal of the primary onco-
genic processes driving cervical neoplasia. Considering the oncogenic role of the trans-
forming genes (E6/HpVgp1 or E7/HpVgp2) of high-risk types of HPVs in the slow
pathogenesis of cervical cancer, therefore, we hypothesized that timely in-situ disrup-
tion or abolition of HPV genome expression within detected high-risk lesions may re-
verse cervical neoplasia. To this end, we identified DNA-binding domains of ZFAs for
engineering ZFNs for targeted mutagenesis of these two high-risk HPV genomes as
precursors for developing a novel gene-therapeutic armament for reversing the primary
oncogenic processes leading to cervical neoplasia. As shown in Additional file 1 and
Additional file 2, plus Additional file 3 and Additional file 4, respectively, multiple un-
paired/single and paired ZFAs (Figures 1, 2, 3 and 4) were initially identified. The
paired ZFAs (pZFAs) were used to model ZFNs that bind and cleave HPV type 16 and
18 genomic DNA (Figures 3 and 4). Because the modeled ZFNs could only target
sequences of the E7 gene of either virus type studied, we focused our additional efforts
on the E6 transforming gene, resulting in another set of two databases of 9 and 14 sin-
gle ZFAs (sZFAs) that bind to sequences of this early gene from both types of HPV
studied (16 and 18, respectively) (Figures 5 and 6).
Many previous studies have explored the therapeutic potential of ZFN technology
against DNA viruses that infect humans, primarily through editing host genomes
[27-30], secondarily by targeting the infective viral genomes [31,32]. ZFNs generally act
by introducing a DSB into the target (say, HPV) genome which in the absence of a
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homologous end-joining (NHEJ) [38-41]. NHEJ is therefore a major mechanism by
which our modeled ZFNs are expected to induce gene architectural disruptions and
functional distortions in the HPVs, although complete HPV gene deletion through
frame-shift mutations is another possibility [33-36,38-41,46]. Towards a similar purpose
[31,32], our model HPV-binding ZFNs would be usable first to cleave and disrupt HPV
type 16 genomic DNA at the contextual positions corresponding to about 0.45
(~3,557 bp), 0.75 (~5,929 bp), and across 0.85 to 0.90. Disabling of these regions, which
correspond to sequences between the early region’s hypothetical protein HpV16gp5
(context 3332-3619 bp) and the major L1 capsid protein (5,560-7,155 bp) (see Figure 3),
may abrogate or reduce HPV type 16 survival or replication fitness. In contrast, HPV
type 18 would be cleaved at regions approximately corresponding to the genomic con-
textual positions 0.1 (~786 bp), 0.25 (~1,964 bp), 0.45 (~3, 535 bp), 0.65 (~5,107 bp),
0.75 (~5,892 bp) and 0.85 (~6,679 bp); or simply the early-gene region (E7, E1, E2, E3,
E4), late region (L2 and L1) and the LCR region (containing the origin of replica-
tion and multiple transcriptional factors) is predicted to be especially susceptible to
similar abrogation or reduction in survival and replication fitness (Figure 4) [37].
Considering the addictive and oncogenic role of the HPV genes E6 and E7 in the
pathogenesis of cervical dysplasia and/or neoplasia [6-10,20], it should be thera-
peutically adequate to target only these genes, explaining our further exploration of
single ZFAs (sZFAs) for the E6 gene of either HPV type studied (Figures 5 and 6).
Secondly, any two of the modular ZFNs cleaving at the extreme 5′ and 3′ ends of a viral
genome could further be modified and optimized [42] to non-specifically target and delete
most (i.e. >90%) of the genomic DNAs of the HPVs studied. In view of the currently evi-
denced low transduction and genome-modification rates of existing vectors and ZFN-
technology, it is important that the success rates of effecting such changes in HPVs within
precancerous lesions of the cervix are evaluated in-vitro and in-vivo, say by using HeLa
cell lines or humanized mouse models [42,47-49]. Thirdly, it is rational to propose use of
those single HPV-genome targeting ZFAs (sZFAHpV) as magnetic drivers for novel HPV-
DNA targeting therapeutics such as transcriptional repressors or the proteosomal/histone
deacetylase (HDAC) inhibitors discussed by Lin et al. [20].
This study has a number of limitations. First, the work has been limited to sequence
analyses and is not accompanied by in-vitro studies. This can be attributed to the lim-
ited resource capacity of our laboratory. However, these same methods [33-36] have
previously been employed successfully to assemble pZFAs that were used to engineer
ZFNs, which have been experimentally proven to be safe and effective [33-44,46]. How-
ever, preclinical studies in-vitro using either a bacterial or yeast hybrid system as
described in the modeling results in section d of our results need to be conducted to
determine the efficacy of the model ZFNHpV before their trial-use in the clinic. Experi-
ments such as those recently conducted by Wilen et al. [47] for the Ad5/F35 vector
carrying CXCR4-specific zinc-finger nucleases used to engineer HIV-resistant human
CD4+ T cells may be conducted in humanized mouse models. Secondly, inclusion of
ZFAs and ZFNs targeting other high risk HPVs, say types 31 and 45, may be a neces-
sary strategy to increase the projected efficacy of this method from 70% (contribution
of HPV types 16 and 18 to global cervical dysplasia) to nearly 100%. Thirdly, it is un-
likely that the entire genomes of these high-risk HPVs will be excised through frame-
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in the HPV genomes could facilitate rare and random yet possibly effective recombina-
tions that may yield either wild-type or mutant HPVs still capable of infecting and
transforming cervical epithelia to cancer. This further underlines the need for the above
proposed safety and efficacy studies. Fourthly, it must be asked how these modeled
HPV-plasmids carrying and transducing ZFNs targeting HPV types 16 and 18 will be
used in the clinic. Our translational projection or proposition is to achieve this via dir-
ect subdermal or intra-epithelial injection into those sites identified by currently exist-
ing screening protocols as pre-cancerous [11-15]. If instituted at the right time, this
would essentially either eliminate the need to use invasive techniques with adverse side
effects (cone-biopsies, cauterizations, cryotherapies, chemo-/radio-therapy) or would at
least supplement them [16,17]. In other words, it would offer a unique opportunity for
medically treating women who did not receive the HPV-vaccine as girls and have never
used potentially effective microbicidal agents such as carrageen [50,51], but have been
diagnosed with pre-cancerous lesions at screening. However, this proposed mode of ad-
ministration is not without its limitations, including uncertainties regarding the cells
that will be targeted using the modeled 2xZFN-gene delivery and transduction, let
alone the efficacy of ZFN-expression and or target-genome modification by the thera-
peutic proteins (ZFNHpV). Also, the delivery plasmids or vectors are potentially prone
to attack by cells of the host immune-system, and concomitant local or systemic im-
munosuppressive (say steroidal) therapy might be needed to avoid this. Lastly, recent
unbiased genome-wide analyses have shown that ZFNs may exhibit off-target effects
in-vivo that might not be predicted by in-silico approaches such as the ones employed
here [48,49].
In conclusion, we present databases of paired ZFAs targeting HPV-genomic-DNA
(pZFAHpV) and their model ZFNHpV for targeting two high-risk HPVs (types 16 and
18). With the appropriate optimization, modification of these modeled ZFNHpV and in-
vivo delivery HPV PsV encapsidation plasmids or vectors, a translational possibility of
therapeutically reversing the primary HPV-induced oncogenic processes driving cer-
vical neoplasia is proposed.
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